The delivery system will be based upon TriLogic drug delivery platform TRI-726 and will be licensed to Mission Pharmacal for future drug development with focus on women’s health medication.
TRI-726 can deliver many actives over several hours to several days and focuses on in-situ gelation, sustained-erosion and bio-resorption, and adhesion.
Mission Pharmacal Commercial Operations president Terry Herring said the company looks forward to working with TriLogic and its new technology.